CDL Karachi Achieves WHO Prequalification, Elevating Drug Testing Standards

Strengthening Pakistan’s Pharmaceutical Credibility

The Central Drugs Laboratory (CDL) Karachi, a statutory facility under the Drug Regulatory Authority of Pakistan (DRAP), has achieved World Health Organization (WHO) prequalification, a milestone that places Pakistan’s drug testing standards on par with global benchmarks.

This certification confirms that CDL’s testing services meet stringent international requirements, ensuring that medicines assessed at the facility are safe, effective, and of high quality. For Pakistan, this recognition is more than symbolic—it represents a leap forward in healthcare regulation and pharmaceutical credibility.

Federal Minister for National Health Services, Syed Mustafa Kamal, hailed the achievement as a “historic moment” for the country. He emphasized that globally compliant drug testing is a critical safeguard for public health and a cornerstone of Pakistan’s shift toward a preventive, quality-focused healthcare system.

The WHO prequalification also strengthens Pakistan’s pharmaceutical industry by enhancing its international credibility. With this recognition, the “Made in Pakistan” brand gains greater acceptance in global markets, opening doors for local manufacturers to expand their reach and compete internationally.

Officials highlighted that the milestone reflects Pakistan’s commitment to modernizing its regulatory framework. DRAP is now positioned to pursue WHO global benchmarking, a move aimed at curbing substandard and counterfeit medicines while ensuring that citizens have access to safe and effective healthcare.

This achievement underscores Pakistan’s progress toward building a robust, transparent, and globally recognized healthcare system. By aligning with WHO standards, CDL Karachi not only strengthens national drug testing capacity but also contributes to the country’s broader vision of healthcare excellence and equity.